688222 Stock Overview
Operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 688222 from our risk checks.
HitGen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.10 |
| 52 Week High | CN¥19.35 |
| 52 Week Low | CN¥8.85 |
| Beta | 0.16 |
| 1 Month Change | -7.21% |
| 3 Month Change | -10.83% |
| 1 Year Change | -33.33% |
| 3 Year Change | -53.87% |
| 5 Year Change | n/a |
| Change since IPO | -74.30% |
Recent News & Updates
HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly
Jun 06
HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors
Mar 07Shareholder Returns
| 688222 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 4.1% | 1.9% | 0.06% |
| 1Y | -33.3% | -37.7% | -16.1% |
Return vs Industry: 688222 exceeded the CN Life Sciences industry which returned -35.5% over the past year.
Return vs Market: 688222 underperformed the CN Market which returned -15.5% over the past year.
Price Volatility
| 688222 volatility | |
|---|---|
| 688222 Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688222's share price has been volatile over the past 3 months.
Volatility Over Time: 688222's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 452 | Li Jin | www.hitgen.com |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGT01 and HGT02, an tumor immunology for cancer.
HitGen Inc. Fundamentals Summary
| 688222 fundamental statistics | |
|---|---|
| Market cap | CN¥4.83b |
| Earnings (TTM) | CN¥64.05m |
| Revenue (TTM) | CN¥409.13m |
75.5x
P/E Ratio11.8x
P/S RatioIs 688222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688222 income statement (TTM) | |
|---|---|
| Revenue | CN¥409.13m |
| Cost of Revenue | CN¥194.35m |
| Gross Profit | CN¥214.79m |
| Other Expenses | CN¥150.74m |
| Earnings | CN¥64.05m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 52.50% |
| Net Profit Margin | 15.66% |
| Debt/Equity Ratio | 14.9% |
How did 688222 perform over the long term?
See historical performance and comparison